Both are on the July 2026 Pharmacy Compounding Advisory Committee agenda for 503A compounding review, which is a separate regulatory question from approval
Early adopters were primarily patients with type 2 diabetes seeking dual metabolic benefits
Mori T, Ohmori H, Luo Y, Mori S, Miyagawa Y, Nukaga S, Goto K, Fujiwara-Tani R, Kishi S, Sasaki T, et al
Khi cc vi khun ny tiu th beta glucan, chng s sn sinh ra cc axit bo chui ngn (short-chain fatty acids - SCFAs), c vai tr quan trng trong vic duy tr sc khe ng rut
While all of these compounds stimulate natural growth hormone release, they differ in their side effects, duration of action, and interaction with other hormones like ghrelin , cortisol , and prolactin
A phase II trial in GHD adults (n=32) reported IGF-1 normalization in 5075% of participants at 30120 g/kg monthly, which was observed to be comparable to daily GH therapy [pubmed.ncbi.nlm.nih.gov]